Plimoth Trust Co. LLC Sells 173 Shares of Johnson & Johnson (NYSE:JNJ)

Plimoth Trust Co. LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 0.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,650 shares of the company’s stock after selling 173 shares during the period. Johnson & Johnson comprises approximately 1.5% of Plimoth Trust Co. LLC’s holdings, making the stock its 18th biggest position. Plimoth Trust Co. LLC’s holdings in Johnson & Johnson were worth $5,118,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Financial Connections Group Inc. bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $348,000. Impax Asset Management Group plc grew its position in shares of Johnson & Johnson by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 86,904 shares of the company’s stock valued at $13,621,000 after purchasing an additional 6,209 shares in the last quarter. Stiles Financial Services Inc increased its holdings in shares of Johnson & Johnson by 2.1% in the fourth quarter. Stiles Financial Services Inc now owns 18,111 shares of the company’s stock worth $2,840,000 after purchasing an additional 376 shares during the last quarter. Keener Financial Planning LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $40,000. Finally, Harbour Trust & Investment Management Co purchased a new position in Johnson & Johnson during the 4th quarter valued at approximately $8,774,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.0 %

Shares of NYSE JNJ opened at $147.49 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The firm has a market capitalization of $355.42 billion, a price-to-earnings ratio of 10.68, a PEG ratio of 2.48 and a beta of 0.53. The stock has a 50 day moving average price of $157.07 and a 200 day moving average price of $155.90. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The firm had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. Johnson & Johnson’s quarterly revenue was down 9.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.35 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Raymond James lifted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Morgan Stanley lowered their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $177.31.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.